2026-06-14T05:07:04Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/181212024-09-21T19:36:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16983
Repisalud
author
Bullón-Vela, Vanessa
author
Abete, Itziar
author
Zulet, Maria Angeles
author
Xu, Yifan
author
Martínez-González, Miguel A
author
Sayón-Orea, Carmen
author
Ruiz-Canela, Miguel
author
Toledo, Estefanía
author
Sánchez, Vicente Martín
author
Estruch, Ramon
author
Lamuela-Raventós, Rosa María
author
Almanza-Aguilera, Enrique
author
Fitó, Montserrat
author
Salas-Salvadó, Jordi
author
Díaz-López, Andrés
author
Tinahones, Francisco J
author
Tur, Josep A
author
Romaguera, Dora
author
Konieczna, Jadwiga
author
Pintó, Xavier
author
Daimiel, Lidia
author
Rodriguez-Mateos, Ana
author
Alfredo Martínez, José
2024-02-12T19:47:22Z
2024-02-12T19:47:22Z
2020-09-22
10.3390/molecules25184340
1420-3049
Molecules (Basel, Switzerland)
http://hdl.handle.net/10668/16308http://hdl.handle.net/20.500.13003/9509
32971870
L632982128
2-s2.0-85091622844
http://hdl.handle.net/20.500.12105/18121
580769100001
Metabolic syndrome (MetS) components are strongly associated with increased risk of non-alcoholic fatty liver disease (NAFLD) development. Several studies have supported that resveratrol is associated with anti-inflammatory and antioxidant effects on health status. The main objective of this study was to assess the putative associations between some urinary resveratrol phase II metabolites, cardiometabolic, and liver markers in individuals diagnosed with MetS. In this cross-sectional study, 266 participants from PREDIMED Plus study (PREvención con DIeta MEDiterránea) were divided into tertiles of total urinary resveratrol phase II metabolites (sum of five resveratrol conjugation metabolites). Urinary resveratrol metabolites were analyzed by ultra- performance liquid chromatography coupled to triple quadrupole mass spectrometry (UPLC-Q-q-Q MS), followed by micro-solid phase extraction (µ-SPE) method. Liver function markers were assessed using serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Moreover, lipid profile was measured by triglycerides, very-low-density lipoprotein cholesterol (VLDL-c), and total cholesterol/high-density lipoprotein ratio (total cholesterol/HDL). Linear regression adjusted models showed that participants with higher total urine resveratrol concentrations exhibited improved lipid and liver markers compared to the lowest tertile. For lipid determinations: log triglycerides (βT3= -0.15, 95% CI; -0.28, -0.02, p-trend = 0.030), VLDL-c, (βT3= -4.21, 95% CI; -7.97, -0.46, p-trend = 0.039), total cholesterol/HDL ratio Moreover, (βT3= -0.35, 95% CI; -0.66, -0.03, p-trend = 0.241). For liver enzymes: log AST (βT3= -0.12, 95% CI; -0.22, -0.02, p-trend = 0.011, and log GGT (βT3= -0.24, 95% CI; -0.42, -0.06, p-trend = 0.002). However, there is no difference found on glucose variables between groups. To investigate the risk of elevated serum liver markers, flexible regression models indicated that total urine resveratrol metabolites were associated with a lower risk of higher ALT (169.2 to 1314.3 nmol/g creatinine), AST (599.9 to 893.8 nmol/g creatinine), and GGT levels (169.2 to 893.8 nmol/g creatinine). These results suggested that higher urinary concentrations of some resveratrol metabolites might be associated with better lipid profile and hepatic serum enzymes. Moreover, urinary resveratrol excreted showed a reduced odds ratio for higher liver enzymes, which are linked to NAFLD.
eng
Antioxidant
Inflammation
Liver enzymes
Metabolic syndrome
Non-alcoholic fatty liver disease
Resveratrol
Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome
research article